http://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Sun, 25 Jun 2017 16:58:27 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Annual Financial Report ]]> http://www.proactiveinvestors.com.au/companies/rns/170623mdc0149j/ Fri, 23 Jun 2017 11:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170623mdc0149j/ <![CDATA[News - Medlab Clinical to begin trials of cannabis based medicines ]]> http://www.proactiveinvestors.com.au/companies/news/179427/medlab-clinical-to-begin-trials-of-cannabis-based-medicines-179427.html Medlab Clinical (ASX:MDC) has received approvals to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial.

NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage cancer patients with intractable pain.

The drug is expected to meet a global need for better pain management, with research having shown cancer pain was an increasingly widespread condition.

Recent statistics regarding cancer pain indicate it is prevalent in 64% of patients with metastatic or advanced-stage disease and that for one in two patients with cancer, it is undertreated.

With the recent U.S. crackdown on opioid abuse, there is a significant need for better, efficacious treatment.

NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures.

The drug is intended to be made available to general practitioners so it would give many Australians access to a drug which governments around the country have been keen to see introduced.

Both clinical trials have received Human Research Ethics Committee (HREC) approvals and are expected to commence shortly.

Recent research on the legal cannabis industry in North America showed consumers spent US$6.9 billion on legal cannabis products in 2016, up 34% from 2015.

]]>
Mon, 19 Jun 2017 12:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/179427/medlab-clinical-to-begin-trials-of-cannabis-based-medicines-179427.html
<![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/170606mdc3423h/ Tue, 06 Jun 2017 17:42:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170606mdc3423h/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/170602mdc0590h/ Fri, 02 Jun 2017 16:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170602mdc0590h/ <![CDATA[RNS press release - Final Results ]]> http://www.proactiveinvestors.com.au/companies/rns/170524mdc0335g/ Wed, 24 May 2017 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170524mdc0335g/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/170515mdc0635f/ Mon, 15 May 2017 08:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170515mdc0635f/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/170512mdc0117f/ Fri, 12 May 2017 12:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170512mdc0117f/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/170511mdc9180e/ Thu, 11 May 2017 16:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170511mdc9180e/ <![CDATA[RNS press release - Abu Dhabi regulatory update ]]> http://www.proactiveinvestors.com.au/companies/rns/170427mdc4780d/ Thu, 27 Apr 2017 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170427mdc4780d/ <![CDATA[RNS press release - Full Year 2017 Trading Update ]]> http://www.proactiveinvestors.com.au/companies/rns/170413mdc3876c/ Thu, 13 Apr 2017 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170413mdc3876c/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/170412mdc2484c/ Wed, 12 Apr 2017 07:30:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170412mdc2484c/ <![CDATA[RNS press release - Swiss regulatory update ]]> http://www.proactiveinvestors.com.au/companies/rns/170410mdc0800c/ Mon, 10 Apr 2017 13:45:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170410mdc0800c/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/170407mdc9607b/ Fri, 07 Apr 2017 14:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/170407mdc9607b/ <![CDATA[RNS press release - Board Committee Changes ]]> http://www.proactiveinvestors.com.au/companies/rns/170320mdc9607z/ Mon, 20 Mar 2017 12:30:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/170320mdc9607z/ <![CDATA[News - Medlab Clinical initiates study of cholesterol lowering oral spray ]]> http://www.proactiveinvestors.com.au/companies/news/174257/medlab-clinical-initiates-study-of-cholesterol-lowering-oral-spray-174257.html Medlab Clinical (ASX:MDC) has signed an agreement to initiate a study to compare how its atorvastatin oral spray compares with statin tablets, like Lipitor, the off-patent market leader.

Statins are a class of drugs often prescribed by doctors to help lower cholesterol levels in the blood. By lowering the levels, they help prevent heart attacks and stroke.

The size of the statin market worldwide, predominantly comprised of tablets, is significant and has been estimated at US$12 billion in 2018.

Medlab’s research to date indicates that a more direct oral spray will enable smaller doses and by reducing dosage, remove much of the statin side effects, reported by about one-third of patients.

The testing of Medlab’s atorvastatin oral spray has been promising, but an independent study is expected to provide objective evidence for those pharma companies which have shown interest.

Medlab’s study agreement is with Zenith Technology Corporation of Dunedin New Zealand, a certified research organisation which does clinical trials and analysis.

Incidentally, Medlab is also completing the final steps to start Australia’s first clinical trial using cannabis for oncology patients suffering intractable pain.

The company’s efforts have been supported by the federal government’s recent announcement to facilitate faster supply of medicinal cannabis products.

Medlab recently obtained clearances from Australian health departments and is awaiting a final shipment clearance from Canadian health authorities to import cannabis material from Canada.

The company’s share price has more than doubled during the past six months, last trading at $0.84.

]]>
Mon, 06 Mar 2017 13:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/174257/medlab-clinical-initiates-study-of-cholesterol-lowering-oral-spray-174257.html
<![CDATA[RNS press release - TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ]]> http://www.proactiveinvestors.com.au/companies/rns/170302mdc3619y/ Thu, 02 Mar 2017 12:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/170302mdc3619y/ <![CDATA[RNS press release - TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ]]> http://www.proactiveinvestors.com.au/companies/rns/170223mdc7064x/ Thu, 23 Feb 2017 14:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/170223mdc7064x/ <![CDATA[News - Medlab Clinical to start Australia’s first trial of cannabis for oncology patients ]]> http://www.proactiveinvestors.com.au/companies/news/173507/medlab-clinical-to-start-australias-first-trial-of-cannabis-for-oncology-patients-173507.html Medlab Clinical (ASX:MDC) is completing the final steps to start Australia’s first clinical trial using cannabis for oncology patients suffering intractable pain.

The company’s efforts have been supported by the federal government’s recent announcement to facilitate faster supply of medicinal cannabis products.

Medlab recently obtained clearances from Australian health departments and is awaiting a final shipment clearance from Canadian health authorities to import cannabis material from Canada.

The cannabis material is a combination of the two most active cannabis ingredients, formulated by Medlab and being supplied by Canadian licenced producer of medical marijuana, Aphria Inc.

Medlab has arranged the delivery of the cannabis material to a contractor in Melbourne, licenced for controlled substance manufacture.

The cannabis material will be incorporated with Medlab’s small particle medicine delivery system, Nanocelle™, to be readied for the trial.

In conjunction with the manufacturer, Medlab has established a drug manufacturing method that will be the prescribed template for future production.

Prerequisites for trial commencement are ethics approval from Royal North Shore Hospital, which is progressing well, and the issue of a clinical trial number from Therapeutic Goods Administration.

Importantly, the supportive government attitude towards cannabis is encouraging for the future prospects of Medlab’s initiative with cannabis.

The company’s share price has more than doubled during the past six months, last trading at $0.755.

Medlab  is well funded with a cash balance of $4.3 million as at 31 December 2016.

]]>
Wed, 22 Feb 2017 13:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/173507/medlab-clinical-to-start-australias-first-trial-of-cannabis-for-oncology-patients-173507.html
<![CDATA[RNS press release - Directorate Change ]]> http://www.proactiveinvestors.com.au/companies/rns/170222mdc5677x/ Wed, 22 Feb 2017 12:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/170222mdc5677x/ <![CDATA[RNS press release - Trading Update ]]> http://www.proactiveinvestors.com.au/companies/rns/170221mdc3759x/ Tue, 21 Feb 2017 07:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/170221mdc3759x/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/161205mdc9894q/ Mon, 05 Dec 2016 13:30:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161205mdc9894q/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/161205mdc9772q/ Mon, 05 Dec 2016 12:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161205mdc9772q/ <![CDATA[RNS press release - TAX TREATMENT FOR SOUTH AFRICAN DIVIDENDS ]]> http://www.proactiveinvestors.com.au/companies/rns/161205mdc9709q/ Mon, 05 Dec 2016 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161205mdc9709q/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/161129mdc3439q/ Tue, 29 Nov 2016 08:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161129mdc3439q/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/161123mdc9660p/ Wed, 23 Nov 2016 14:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161123mdc9660p/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/161116mdc3351p/ Wed, 16 Nov 2016 12:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161116mdc3351p/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/161115mdc2579p/ Tue, 15 Nov 2016 16:15:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161115mdc2579p/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/161115mdc2436p/ Tue, 15 Nov 2016 14:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161115mdc2436p/ <![CDATA[RNS press release - Interim Results ]]> http://www.proactiveinvestors.com.au/companies/rns/161110mdc8328o/ Thu, 10 Nov 2016 07:21:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/161110mdc8328o/ <![CDATA[RNS press release - Pre-Close Trading Update ]]> http://www.proactiveinvestors.com.au/companies/rns/160927mdc8760k/ Tue, 27 Sep 2016 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160927mdc8760k/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/160923mdc6822k/ Fri, 23 Sep 2016 11:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160923mdc6822k/ <![CDATA[RNS press release - Notification of Trading Update ]]> http://www.proactiveinvestors.com.au/companies/rns/160919mdc1143k/ Mon, 19 Sep 2016 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160919mdc1143k/ <![CDATA[RNS press release - Announcement in respect of MPILO arrangements ]]> http://www.proactiveinvestors.com.au/companies/rns/160916mdc9984j/ Fri, 16 Sep 2016 10:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160916mdc9984j/ <![CDATA[RNS press release - Trading Update And Middle East Integration ]]> http://www.proactiveinvestors.com.au/companies/rns/160909mdc3787j/ Fri, 09 Sep 2016 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160909mdc3787j/ <![CDATA[News - Medlab Clinical Ltd initiates Phase 2a after positive anti-depression results ]]> http://www.proactiveinvestors.com.au/companies/news/165626/medlab-clinical-ltd-initiates-phase-2a-after-positive-anti-depression-results-70734.html Medlab Clinical Ltd (ASX:MDC) will initiate Phase 2a human trial of its anti-depression therapy following encouraging results from Phase 1. 

Participants in the Phase 1 human trials were administered a Medlab formulation named NRGBiotic to assess whether it could improve depression symptoms and clinical outcomes. 

The first trial of eight weeks showed significant improvement in 80% of the trial cohort, with the second trial of the same period showing further improvement in +90% of the trial cohort.

Medlab is proceeding immediately to Phase 2a human clinical studies on the basis of these significant results.

In initiating the Phase I trial, Medlab hypothesised that treatment-resistant depression may be due to a combination of altered neurophysiological and poor gut health issues. 

The hypothesis has been influenced by the Human Microbiome Project, a five year project by the U.S. National Institute of Health aimed at understanding the role of bacteria living in and on humans. 

Medlab has formulated NRGBiotic as a bacteria-based medicine that targets the gut–brain axis to treat patients diagnosed with treatment-resistant depression. 

Importantly, the outcomes from the Phase I trial were positive for the underlying hypothesis and the application of NRGBiotic. 

The Australian Bureau of Statistics has estimated 45% of Australians aged 16-85 years have met the criteria for a diagnosis of a mental disorder at some point in their lives. 

Medlab is looking to participate in Australia’s mental illness market which costs the country in the order of $20 billion annually.

The company’s share price has increased by 80% during the past 6 months, trading at $0.375.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 30 Aug 2016 11:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/165626/medlab-clinical-ltd-initiates-phase-2a-after-positive-anti-depression-results-70734.html
<![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/160802mdc0175g/ Tue, 02 Aug 2016 13:30:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160802mdc0175g/ <![CDATA[RNS press release - Result of AGM ]]> http://www.proactiveinvestors.com.au/companies/rns/160720mdc7882e/ Wed, 20 Jul 2016 17:07:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160720mdc7882e/ <![CDATA[RNS press release - Completion of Successful Refinancing ]]> http://www.proactiveinvestors.com.au/companies/rns/160628mdc5342c/ Tue, 28 Jun 2016 15:45:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160628mdc5342c/ <![CDATA[RNS press release - Annual Financial Report ]]> http://www.proactiveinvestors.com.au/companies/rns/160621mdc7063b/ Tue, 21 Jun 2016 09:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160621mdc7063b/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/160617mdc5905b/ Fri, 17 Jun 2016 14:30:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160617mdc5905b/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/160615mdc3177b/ Wed, 15 Jun 2016 16:29:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160615mdc3177b/ <![CDATA[RNS press release - Middle East Site Visit ]]> http://www.proactiveinvestors.com.au/companies/rns/160615mdc0619b/ Wed, 15 Jun 2016 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160615mdc0619b/ <![CDATA[RNS press release - Final Results ]]> http://www.proactiveinvestors.com.au/companies/rns/160525mdc1973z/ Wed, 25 May 2016 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160525mdc1973z/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/160517mdc5032y/ Tue, 17 May 2016 14:14:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160517mdc5032y/ <![CDATA[RNS press release - Appointment of Group Chief Financial Officer ]]> http://www.proactiveinvestors.com.au/companies/rns/160511mdc7120x/ Wed, 11 May 2016 07:00:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/160511mdc7120x/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/160215anh1366p/ Mon, 15 Feb 2016 17:42:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/160215anh1366p/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> http://www.proactiveinvestors.com.au/companies/rns/160215anh1280p/ Mon, 15 Feb 2016 16:40:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/160215anh1280p/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.com.au/companies/rns/160215anh1270p/ Mon, 15 Feb 2016 16:35:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/160215anh1270p/ <![CDATA[RNS press release - Change of Name ]]> http://www.proactiveinvestors.com.au/companies/rns/160215anh1142p/ Mon, 15 Feb 2016 15:30:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/160215anh1142p/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/160215anh0058p/ Mon, 15 Feb 2016 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/rns/160215anh0058p/